Biontech Se

This study tests an experimental mRNA vaccine called BNT166a to see if it is safe and can protect against mpox (monkeypox). About 310 healthy adults in Africa will receive either the vaccine or a placebo. The trial is double-blind, meaning neither participants nor doctors know wh…

This trial is testing an updated version of the BNT162b2 COVID-19 vaccine in healthy adults aged 18 to 64. Participants will receive either the updated COVID-19 vaccine or a Tdap vaccine (for tetanus, diphtheria, and whooping cough) to compare safety and measure spike protein lev…

This study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This early-stage study tests a new antibody called BNT351 in 67 adults, both with and without HIV. The goal is to check safety, how long the antibody stays in the blood, and whether it can lower HIV levels in people with the virus. It is a first step toward possibly controlling H…

This study tests two experimental drugs, BNT326 and BNT327, in people with advanced non-small cell lung cancer that has spread or come back. The trial has three parts to find the best dose and check safety, and will compare the combination to standard treatments like pembrolizuma…

This phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…

This study tests a new drug called BNT327 combined with standard chemotherapy in adults with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination shrinks tumors better than chemo alone. About 105 participants will be enrolled, and r…

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug (atezolizumab) plus the same chemo. About 621 adults who have not yet been treated for their can…

This early-stage trial is testing a new cancer vaccine called BNT116, alone or with other drugs, in people with advanced non-small cell lung cancer. The main goal is to find a safe dose and check for side effects. About 320 participants will be enrolled across several groups, inc…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This Phase 3 trial tests whether the drug BNT323 (trastuzumab pamirtecan) works better than standard chemotherapy for people with recurrent endometrial cancer that expresses HER2. About 480 participants will be split into two groups based on their HER2 levels. The study measures …

This trial tests whether adding a vaccine called BNT113 to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer linked to HPV16. About 350 participants will receive either the combination or the standard single d…

This study tests a new drug called BNT324 against standard chemotherapy (docetaxel) in men with metastatic castration-resistant prostate cancer that has progressed after hormone therapy. The goal is to see if BNT324 helps patients live longer without their cancer worsening. About…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This study is testing two experimental drugs, BNT324 and BNT327, together in people with advanced lung cancer that has spread or come back. BNT324 targets and delivers a toxin to cancer cells, while BNT327 helps the immune system attack tumors and cuts off their blood supply. The…

This study is testing whether adding two new drugs (BNT314 and BNT327) to standard chemotherapy can help people with metastatic colorectal cancer that hasn't responded well to initial treatment. The trial will enroll about 482 participants across multiple sites. The goal is to se…

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This phase 2 trial tests two drugs, pumitamig and bevacizumab, alone or together with temozolomide, in 75 adults whose glioblastoma has returned after standard treatment. The goal is to see if these combinations can shrink tumors and control the disease. Participants will receive…

This study tests a new drug called pumitamig (BNT327) combined with standard chemotherapy (docetaxel) in 60 people with advanced non-small cell lung cancer that got worse after initial treatment. The goal is to see if the combination is safe and shrinks tumors. It is an early-pha…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …